Martin Shkreli’s old companies secure $650,000 deal to sell Daraprim amid bankruptcy

Dara­prim, the an­ti-malar­i­al and an­ti-par­a­sitic at the heart of “Phar­ma Bro” Mar­tin Shkre­li’s price-goug­ing no­to­ri­ety, is chang­ing hands once again.

Vy­era Phar­ma­ceu­ti­cals — for­mer­ly known as the Shkre­li com­pa­ny Tur­ing Phar­ma­ceu­ti­cals — and its par­ent com­pa­ny Phoenixus struck a deal to sell Dara­prim rights as part of its Chap­ter 11 bank­rupt­cy pro­ceed­ings. For $650,000, they will hand off both Dara­prim and a hy­per­ten­sive drug called Ve­camyl and post-clos­ing li­a­bil­i­ties for the drugs, the com­pa­nies an­nounced on Tues­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters